Eccogene will receive a $60 million payment from AstraZeneca (AZN), which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase 2b program. VISTA and SOLSTICE are two global Phase 2b multicenter trials assessing the efficacy and safety of ECC5004/AZD5004, administered orally, once daily, to participants who are obese or overweight with at least one weight-related comorbidity and type 2 diabetes, respectively. AstraZeneca licensed the global rights to ECC5004/AZD5004 from Eccogene in November 2023, for which the Company received an upfront payment of $185 million and can receive up to $1.825 billion in future milestones, as well as royalty payments. Eccogene retains co-development and co-commercialization rights to ECC5004/AZD5004 in China.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- CytoSorbents announces FDA has accepted De Novo medical device application
- Ionis Pharmaceuticals announces CHMP recommends approval for Wainzua
- Hutchmed announces results from SAVANNAH trial
- AstraZeneca, Daiichi Sankyo announces Enhertu approved in China
- Election 2024: Where To Put Your Money Ahead of the Vote